TABLE 3.
Evaluation of factors associated with the survival of anti-TNF therapies
| Univariate analysis | Enter model | |||||
|---|---|---|---|---|---|---|
| Variables | HR | 95% CI | p | HR | 95% CI | p |
| Age | 0.989 | 0.956-1.023 | 0.507 | 0.961 | 0.916-1.008 | 0.100 |
| BMI | 0.987 | 0.912-1.069 | 0.755 | 0.980 | 0.875-1.097 | 0.721 |
| Disease duration | 1.006 | 0.944-1.073 | 0.847 | |||
| Number of comorbidity | 1.022 | 0.680-1.534 | 0.917 | 0.992 | 0.620-1.588 | 0.973 |
| Previous number of bDMARD | 0.940 | 0.688-1.286 | 0.701 | 0.816 | 0.566-1.178 | 0.278 |
| Previous number of csDMARD | 1.637 | 0.713-3.757 | 0.245 | 1.614 | 0.606-4.302 | 0.338 |
| Types of anti-TNF | ||||||
| Wo/Fc | ||||||
| W/Fc | 1.690 | 0.573-4.984 | 0.341 | 2.011 | 0.593-6.821 | 0.262 |
| RF status | ||||||
| Negative Positive |
3.961 | 0.924-16.976 | 0.064 | |||
| RF titers | 1.005 | 1.001-1.008 | 0.010* | 1.007 | 1.002-1012 | 0.009* |
| RF | ||||||
| ≤42 IU/mL >42 IU/mL |
1.954 | 0.827-4.619 | 0.127 | |||
| Anti-CCP status | ||||||
| Negative Positive |
2.963 | 0.999-8.790 | 0.050 | 1.837 | 0.563-5.992 | 0.313 |
| MTX | ||||||
| Yes | ||||||
| No | 0.777 | 0.343-1.764 | 0.547 | 0.645 | 0.266-1560 | 0.330 |
| Steroid usage | ||||||
| Yes | ||||||
| No | 0.587 | 0.256-1.347 | 0.209 | 0.392 | 0.153-1.004 | 0.051 |
*
: P<0.05; BMI: Body mass index; bDMARD: Biological disease-modifying antirheumatic drug; csDMARD: Conventional synthetic disease-modifying antirheumatic drug; CI: Confidence interval; RF: Rheumatoid factor; w/Fc: With Fc; wo/Fc: Without Fc.